Industry Daily Summary
Industry Daily Summary: What Happened on October 3, 2026
Novartis commits $575 million upfront for Abogen’s mRNA T-cell engager
The deal includes options worth up to $7.2 billion in potential milestones. Cardinal Health and McKesson extended CVS distribution agreements through 2032.
Covers October 2 and October 3. There was no summary on October 2.
Today in brief
Novartis agreed to pay Abogen Biosciences $575 million upfront for worldwide rights to its experimental mRNA-encoded T-cell engager ABO2203 and options on other programs.12 If Novartis exercises every option and the programs meet their milestones, Abogen could receive up to $7.2 billion more.12
Cardinal Health extended its CVS distribution arrangement through June 2032, while McKesson agreed in principle to extend its arrangement through the same month.3
Novartis takes worldwide rights to Abogen’s mRNA T-cell engager
Novartis will pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to ABO2203, with options to license additional programs from Abogen’s RNA platform.12 Abogen could receive up to $7.2 billion in development, regulatory and commercial milestones if Novartis exercises all options and the programs meet the required milestones, plus possible sales royalties.12
ABO2203 uses lipid nanoparticles to deliver mRNA that instructs cells to produce a protein linking CD3 on T cells with CD19 on B cells, directing the T cells to kill B cells.24 The approach is intended to deplete B cells in autoimmune disease, and the drug is being studied in Phase 1 trials for autoimmune conditions and B-cell non-Hodgkin lymphoma.24
Early oncology data came from nine people with relapsed or refractory B-cell non-Hodgkin lymphoma, not autoimmune disease.2 Abogen reported response rates of 33%, 67% and 100% across three dose groups. The small, early-stage study cannot establish how the treatment will perform in autoimmune conditions.2
The agreement remains subject to customary closing requirements, including regulatory clearances.25
Three pharma deals in China carry at least $300 million upfront
Three agreements involving Merck, Novo Nordisk and Novartis each included at least $300 million upfront for an asset with little or no clinical data, and each could exceed $2 billion in total value.6 The deals span different disease areas and treatment types, extending China-related pharma partnering beyond cancer antibody programs, according to BioCentury’s analysis.6
Cardinal Health and McKesson extend CVS distribution arrangements through 2032
Cardinal Health entered a binding letter of intent to extend its existing CVS Health distribution arrangement through June 30, 2032, with the current service scope continuing.3 McKesson reached an agreement in principle covering CVS mail-order, specialty and retail pharmacies, along with distribution centers, through June 2032. It still needs to sign a definitive contract.3
CVS accounted for 28% of Cardinal Health’s fiscal 2026 revenue and about 24% of McKesson’s consolidated revenue in that fiscal year.3